Krishna Reddy, MD, PhD, explores the roles of sequential and concurrent chemoradiotherapy (sCRT and cCRT) in patients with unresectable stage III NSCLC, delving into considerations for selecting between the two approaches and examining potential variations in treatment based on factors such as age, performance status (PS), or comorbidities.
Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.